Is HRT Safe for the Heart? 2026 Safety & Risks Guide

Why the HRT-Heart Question Is Complicated

The short answer is that HRT is not uniformly safe or unsafe for the heart. It depends on when a woman starts therapy, which formulation she uses, and what her baseline cardiovascular risk profile looks like.

For decades, HRT was prescribed widely for cardiovascular protection. Then the Women's Health Initiative (WHI) shook that confidence in 2002. Then newer trials and re-analyses rebuilt a more nuanced picture. Understanding that arc helps clarify where the science stands now.

The WHI Changed Everything, and Was Misread

The WHI estrogen-plus-progestin arm (N=16,608) was stopped early in 2002 after a mean follow-up of 5.6 years because of increased invasive breast cancer incidence. The hazard ratio for coronary heart disease (CHD) was 1.24 (95% CI 1.00 to 1.54), a statistically marginal finding 1.

What the headlines missed: the average age of WHI participants was 63, and the average time since menopause was 12 years. These were not recently menopausal women. Applying those results to a 50-year-old starting HRT for hot flashes represents a systematic age-conflation that distorted clinical practice for two decades.

The Estrogen-Alone Arm Told a Different Story

The WHI estrogen-alone arm (N=10,739, hysterectomized women) showed a hazard ratio for CHD of 0.91 (95% CI 0.75 to 1.12), meaning no statistically significant increase, and a non-significant trend toward benefit 2. Among women aged 50 to 59 in that arm, the hazard ratio for CHD was 0.63 (95% CI 0.36 to 1.09), suggesting a possible protective effect 2.

These data were available years before clinical practice caught up with them.

The Timing Hypothesis: What It Means and Why It Matters

The timing hypothesis holds that estrogen's effect on the cardiovascular system depends heavily on when in the disease trajectory it is introduced. Estrogen applied to healthy, plaque-free arteries may slow atherosclerosis. Estrogen applied to arteries already carrying established plaques may destabilize them.

ELITE: The Strongest Trial Evidence for Timing

The Early versus Late Intervention Trial with Estradiol (ELITE, N=643) randomized postmenopausal women to oral 17-beta-estradiol 1 mg daily (plus vaginal progesterone gel for those with a uterus) or placebo, stratified by time since menopause: under 6 years ("early") versus 10 or more years ("late") 3.

After a median 5 years of treatment, the early-initiation group showed significantly slower progression of carotid intima-media thickness (CIMT), a validated surrogate marker for atherosclerosis. The mean CIMT progression rate was 0.0078 mm/year in the estradiol group versus 0.0100 mm/year in the placebo group (P<0.001 for interaction with timing) 3. In the late-initiation group, no such benefit appeared.

DOPS: Hard Clinical Outcomes in Early Initiators

The Danish Osteoporosis Prevention Study (DOPS, N=1,006) followed women randomized to HRT or no treatment, beginning shortly after menopause or oophorectomy, for up to 16 years. At 10-year follow-up, women in the HRT group had a significantly lower rate of the composite endpoint (death, myocardial infarction, or heart failure): hazard ratio 0.48 (95% CI 0.26 to 0.87), P=0.015 4. That is a 52% reduction in composite cardiovascular events.

DOPS used oral estradiol with or without norethisterone acetate. Mortality alone showed a hazard ratio of 0.43 (95% CI 0.19 to 0.98) in favor of HRT 4.

KEEPS: Atherosclerosis Markers in Early Menopause

The Kronos Early Estrogen Prevention Study (KEEPS, N=727) randomized women who were 6 to 36 months post-menopause to oral conjugated equine estrogen (CEE) 0.45 mg/day, transdermal estradiol 50 mcg/day, or placebo for 4 years. Neither active arm significantly changed CIMT progression compared to placebo, but both were associated with favorable effects on mood, bone density, and sexual function 5. The study was underpowered for hard cardiac events and should not be read as evidence of no benefit.

Formulation Matters: Route of Delivery and Cardiovascular Risk

Not all HRT is the same. The route by which estrogen enters the bloodstream and the type of progestogen added to protect the uterus each carry distinct cardiovascular implications.

Oral vs. Transdermal Estrogen and Clot Risk

Oral estrogen undergoes first-pass hepatic metabolism, stimulating production of clotting factors and C-reactive protein. Transdermal estrogen bypasses the liver and avoids those effects.

A large French case-control study (N=271 cases) found that oral estrogen use was associated with a four-fold increased risk of venous thromboembolism (VTE) compared to non-users (adjusted OR 4.0, 95% CI 1.9 to 8.3), while transdermal estrogen was not associated with significantly elevated VTE risk (adjusted OR 0.9, 95% CI 0.4 to 2.1) 6.

A 2019 UK primary care cohort study (N=over 900,000 women) published in the BMJ confirmed this pattern: transdermal estradiol was not associated with increased VTE risk at any dose studied, while oral estradiol and oral CEE both showed elevated VTE hazard ratios 7.

For stroke risk, evidence similarly favors the transdermal route. A meta-analysis in the BMJ (2010) found that oral but not transdermal estrogen was associated with increased ischemic stroke risk 8.

Progestogen Type: Micronized Progesterone vs. Synthetic Progestins

The progestogen chosen to protect the uterus in women who have not had a hysterectomy also appears to shift cardiovascular risk.

Medroxyprogesterone acetate (MPA), the synthetic progestin used in the WHI estrogen-plus-progestin arm, has been shown to partially antagonize estrogen's favorable effects on coronary vasomotion and lipid profiles in primate models 9.

Micronized progesterone (body-identical progesterone, e.g., Prometrium/Utrogestan) does not carry the same receptor-binding profile. The French E3N cohort study (N=80,377 women-years of follow-up) found that women using transdermal estrogen combined with micronized progesterone had no elevated MI or stroke risk, while those using synthetic progestins had a non-significant trend toward higher stroke rates 10.

The 2022 NAMS position statement notes: "Micronized progesterone and dydrogesterone appear to have a more favorable cardiovascular and metabolic profile than older synthetic progestins" 11.

Risk Stratification: Who Benefits, Who Should Avoid HRT

Blanket rules fail patients. The correct question is whether a specific woman's cardiovascular benefit outweighs her individual risk.

Women Who Are Likely to Benefit Cardiovascularly

Women who meet all of the following generally have a favorable risk-benefit profile for HRT with respect to cardiovascular outcomes:

• Age under 60 or within 10 years of menopause onset
• No pre-existing coronary artery disease, prior MI, or stroke
• No active or recent VTE
• No inherited thrombophilia (e.g., Factor V Leiden, prothrombin mutation)
• Moderate-to-severe vasomotor symptoms reducing quality of life

For these women, the Endocrine Society Clinical Practice Guideline (2015, reaffirmed 2023) states: "We recommend that menopausal hormone therapy be used to treat symptoms in healthy menopausal women younger than 60 years or within 10 years of menopause onset without contraindications" 12.

Women Who Require Individualized Assessment

Women with one or more of the following need case-by-case evaluation before starting HRT:

• Hypertension (controlled hypertension is not an absolute contraindication, but uncontrolled hypertension is)
• Obesity (BMI above 30 raises baseline VTE risk)
• Migraine with aura (associated with increased stroke risk independent of HRT)
• Family history of early cardiovascular disease
• Elevated baseline LDL or established dyslipidemia

For these patients, transdermal estrogen combined with micronized progesterone represents the lowest-risk regimen if therapy is indicated.

Women for Whom HRT Is Contraindicated Cardiovascularly

Absolute cardiovascular contraindications include:

• Active or recent VTE or pulmonary embolism
• Known coronary artery disease or recent acute coronary syndrome
• Recent ischemic stroke or TIA
• Known inherited thrombophilia without anticoagulation

The North American Menopause Society (NAMS) 2022 Hormone Therapy Position Statement lists these as contraindications regardless of symptom severity 11.

Specific Cardiovascular Outcomes: What the Numbers Show

Coronary Heart Disease

In healthy women aged 50 to 59 from the WHI estrogen-alone arm, the adjusted CHD hazard ratio was 0.63, suggesting possible protection 2. In DOPS early initiators, the composite cardiovascular endpoint showed a 52% reduction 4. A 2015 Cochrane review of 19 randomized trials found that HRT started within 10 years of menopause was associated with reduced all-cause mortality (OR 0.70, 95% CI 0.52 to 0.95) and reduced CHD events (OR 0.52, 95% CI 0.29 to 0.96) compared to placebo 13.

Stroke

Stroke risk with oral estrogen is elevated. The WHI estrogen-plus-progestin arm showed an HR of 1.31 for ischemic stroke 1. Transdermal estrogen does not appear to carry this risk at standard doses, based on both the French E3N cohort and the 2010 BMJ meta-analysis 8.

Venous Thromboembolism

Baseline VTE incidence in postmenopausal women is roughly 3 to 4 per 1,000 women per year. Oral estrogen approximately doubles that rate. Transdermal estrogen does not significantly raise it 6, 7.

Atrial Fibrillation

Data on HRT and atrial fibrillation (AF) are limited. A Danish national registry study (N=over 300,000) found no significant increase in AF risk with HRT use overall, and a trend toward reduced AF in younger initiators 14.

How Current Guidelines Position HRT in 2026

Three major bodies have converged on largely consistent recommendations.

The NAMS 2022 Position Statement concludes: "For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture" 11.

The Endocrine Society agrees that HRT is appropriate for symptomatic women under 60 without cardiovascular contraindications 12.

The British Menopause Society and Women's Health Concern similarly state that "there is no increased cardiovascular risk for women starting HRT below 60 years of age" and that transdermal preparations are preferred when any cardiovascular risk factors exist 15.

None of these guidelines recommend HRT solely for cardiovascular prevention in the absence of symptoms. Secondary cardiovascular prevention (using HRT to treat women who already have established heart disease) remains unsupported by current evidence.

Practical Prescribing Considerations

Preferred Formulations for Women With Cardiovascular Risk Factors

For women with hypertension, obesity, migraine with aura, or a personal or family history of VTE, clinicians generally favor:

• Transdermal 17-beta-estradiol (patch, gel, or spray) rather than oral CEE or oral estradiol
• Micronized progesterone (oral 100 to 200 mg nightly or vaginally) rather than MPA or norethisterone acetate
• Starting at the lowest effective dose, with titration based on symptom response

Monitoring During HRT

Women on HRT with any cardiovascular risk factor should have:

• Blood pressure checked at baseline and at 3 months after initiation
• Fasting lipid panel at baseline (oral estrogen raises triglycerides; transdermal estrogen is largely lipid-neutral)
• Assessment for new risk factors at each annual review

Duration of Therapy

No blanket time limit applies to appropriately selected women. The NAMS 2022 statement explicitly rejects arbitrary 5-year cutoffs: "duration limits should not be placed on therapies when being used for symptom management" in low-risk women 11. A shared-decision review of risks and benefits every 1 to 2 years is appropriate.

What Women With Pre-Existing Heart Disease Should Know

HRT is generally not recommended for women with established coronary artery disease (CAD), prior MI, or prior stroke, based on the HERS trial (N=2,763), which found no reduction in recurrent CHD events in women with known CAD randomized to CEE plus MPA versus placebo (HR 0.99, 95% CI 0.80 to 1.22 over 4.1 years) and an early increase in events in year one 16.

HERS II (follow-up to 6.8 years) confirmed no long-term benefit in this population 17.

These data apply specifically to women with pre-existing CAD. They should not be extrapolated to healthy, recently menopausal women without cardiac history, which is a common and persistent misapplication of the HERS findings.